Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

FDA clears LigaSure for Hugo RAS

Analysis based on 7 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026

Sentiment
5
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The FDA clearance strengthens Medtronic's competitive position in the fast-growing robotic-assisted surgery market by adding a differentiated vessel-sealing instrument to its Hugo platform, which could support incremental system placements and procedure volumes in the U.S. The news is modestly positive for Medtronic shares but is unlikely to move broad markets, as it represents an incremental product expansion rather than a major revenue event.

medical devices healthcare robotic surgery

Medtronic announced on September 16, 2026 that the U.S. United States — Food and Drug Administration cleared the LigaSure RAS Maryland jaw device for use with the Hugo robotic-assisted surgery system. The clearance expands the instruments available on the Hugo RAS platform and brings Medtronic's vessel-sealing technology into robotic-assisted procedures in the United States. The LigaSure RAS Maryland instrument is designed exclusively for use with the Valleylab FT10 energy platform on the Hugo RAS system, sealing and cutting vessels, thick tissue, and lymphatics up to 7 mm in diameter in approximately two seconds while minimizing thermal spread. It is the first robotic-driven LigaSure instrument, building on vessel-sealing technology used in more than 45 million procedures across 65 countries over two decades. The Hugo RAS system is currently cleared in the U.S. only for urologic surgical procedures and is in commercial use at a growing number of hospitals. Medtronic said it is working to expand Hugo indications to general and gynecologic soft-tissue procedures in the U.S. Outside the U.S., the Hugo system has been used in more than 35 countries across over 50 surgical procedures. The LigaSure RAS Maryland instrument was introduced on the Hugo system in Europe in 2025 following CE Mark approval. Dr. Matthew Kroh, chief medical officer within Medtronic's Surgical business, said the clearance means surgeons carry the confidence and control they already rely on into robotic-assisted cases. Medtronic is headquartered in Galway, Ireland.

stock
Medtronic is the central actor, receiving FDA clearance for the LigaSure RAS Maryland device on its Hugo RAS system, which expands its robotic surgery portfolio and could support future U.S. revenue growth.
Importance 95.0 Sentiment 15.0
govactor
The FDA granted the clearance that enables U.S. commercialization of the LigaSure RAS Maryland instrument on the Hugo system, acting as the key regulatory gatekeeper for the event.
Importance 70.0 Sentiment 0.0
cnt
The United States is the market where the FDA clearance applies, expanding the availability of the LigaSure RAS Maryland instrument and the Hugo RAS system for U.S. surgeons and hospitals.
Importance 40.0 Sentiment 0.0
per
Matthew Kroh, Medtronic's Surgical business chief medical officer, provided a supporting quote on the clinical value of bringing LigaSure vessel-sealing to the Hugo RAS system.
Importance 20.0 Sentiment 0.0
cnt
Ireland is noted as the headquarters location of Medtronic in Galway, giving it a minor contextual role in the announcement.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.